AHA GUIDELINES Bundle (free trial)

Management of Adults With Congenital Heart Disease

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1541979

Contents of this Issue

Navigation

Page 67 of 93

68 Specific Conditions Figure 6. Indications for Pulmonary Valve Replacement in Repaired Tetralogy of Fallot * Pulmonary valve dysfunction defined as moderate PR (CMR-derived RF ≥25%) or RVSP >2/3 systemic pressure due to RVOTO. CMR indicates cardiovascular magnetic resonance; ESVi, end-systolic volume index; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; PR, pulmonary regurgitation; RF, regurgitant fraction; RV, right ventricular; RVEDV, right ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; RVOTO, right ventricular outflow tract obstruction; RVSP, right ventricular systolic pressure; TOF, tetralogy of Fallot; and TR, tricuspid regurgitation. Repaired TOF with moderate or greater pulmonary valve dysfunction* NO YES Symptomatic? 1 Pulmonary valve replacement 2a Pulmonary valve replacement 2a Pulmonary valve replacement Progressive decrease in ventricular function ≥2 of the following: • RV ESVi >80 mL/m 2 • RVEDV ≥2× LVEDV • RVEF ≤46% • LVEF ≤50% • Progressive decrease in exercise capacity

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Management of Adults With Congenital Heart Disease